Lupin receives EIR from USFDA for Chhatrapati Sambhajinagar facility

13 Nov 2025 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility, following a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2369.00 28.25 (1.21%)
11-Mar-2026 10:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1829.40
Dr. Reddys Lab 1328.50
Cipla 1329.05
Zydus Lifesciences 931.70
Lupin 2369.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×